Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07712939Phase 1Recruiting

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

Role: lead

NCT07408869Phase 1Withdrawn

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

Role: lead

NCT07236411Phase 1Completed

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Role: lead

NCT07597200Phase 1Recruiting

A Clinical Study of Cizutamig in Thyroid Eye Disease

Role: lead

NCT07052032Phase 1Active Not Recruiting

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Role: lead

NCT07215663Phase 1Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Role: lead

NCT07215650Phase 1Recruiting

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Role: lead

All 7 trials loaded